Monitor upcoming topline data from the Phase 2a PreciSION CF trial and Phase 1 dual combination trial, expected this summer — these are the primary catalysts for SION. The current cash runway into 2028 provides ample time for data readouts without near-term financing risk.
Price Chart
Executive Summary
Sionna Therapeutics reported Q2 2026 financial results with a net loss of $29.9M ($-0.66/share), wider than the $18.1M loss in Q2 2025, driven by increased R&D and G&A spending. The filing is a routine quarterly update for a pre-revenue clinical-stage biotech, with no new clinical data or guidance changes — both key pipeline trials remain on track for topline data this summer. Cash burn continues as expected, with $268.3M in cash funding operations into 2028, making this a neutral event with no material surprise vs expectations.
Key Financial Metrics
Key Facts
- Net loss of $29.9M for Q2 2026 vs $18.1M in Q2 2025, driven by higher R&D ($21.9M vs $15.4M) and G&A ($10.6M vs $6.5M) expenses.
- Cash, cash equivalents, and marketable securities totaled $268.3M as of June 30, 2026, expected to fund operations into 2028.
- PreciSION CF Phase 2a trial of SION-719 and Phase 1 dual combination trial of SION-451 both remain on track for topline data in summer 2026.
- EPS of $-0.66 for Q2 2026 vs consensus estimate of $-0.64 (a 3.1% miss).
- No revenue reported; company is a pre-revenue clinical-stage biopharmaceutical company.
Financial Impact
Net loss widened by $11.8M YoY to $29.9M; cash burn of $42M in H1 2026 vs $24M in H1 2025; no revenue
Risk Factors
- Phase 2a and Phase 1 trial data may fail to meet efficacy or safety endpoints, which would significantly impair the stock.
- Widening net losses and increasing cash burn rate could necessitate future dilutive financing if timelines extend beyond current cash runway.
- Competitive landscape from existing CFTR modulators (e.g., Trikafta) may limit commercial potential even if trials succeed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-053832 |
| Document: sion-20260806.htm | 0001628280-26-053832 |
| Document: 0001628280-26-053832-index-headers.html | 0001628280-26-053832 |
| Document: 0001628280-26-053832-index.html | 0001628280-26-053832 |
| Document: 0001628280-26-053832.txt | 0001628280-26-053832 |
| 8-K Data (Synthetic) | 0001628280-26-053832 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $4.50 $7.30 | ▼ −62.22% | ▼ −63.14% | $5.04 (−12.00%) |
Aug 6, 2026 8w ago | 8-K | $49.61 $6.75 | ▼ −86.39% | ▼ −86.99% | $5.04 (−89.84%) |
Jul 9, 2026 12w ago | Insider Cluster | $45.29 $51.04 | ▲ +12.70% | ▲ +10.27% | $5.04 (−88.87%) |
Jul 9, 2026 12w ago | Insider Cluster | $45.29 $51.04 | ▼ −12.70% | ▼ −10.27% | $5.04 (+88.87%) |
Jul 7, 2026 12w ago | Insider Cluster | $44.00 $47.34 | ▼ −7.59% | ▼ −4.32% | $5.04 (+88.55%) |
Jul 2, 2026 13w ago | Insider Cluster | $43.99 $46.78 | ▲ +6.34% | ▲ +6.76% | $5.04 (−88.54%) |
Jun 11, 2026 16w ago | Institutional Cluster | $36.05 $44.94 | ▲ +24.66% | ▲ +22.77% | $5.04 (−86.02%) |
May 30, 2026 17w ago | Insider Cluster | $40.90 $43.99 | ▲ +7.55% | ▲ +8.85% | $5.04 (−87.68%) |
May 29, 2026 17w ago | 144 | $40.90 $43.99 | ▼ −7.55% | ▼ −8.85% | $5.04 (+87.68%) |
May 12, 2026 20w ago | 8-K | $40.94 $34.03 | ▼ −16.88% | ▼ −15.15% | $5.04 (−87.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access